Are You Receiving Treatment with Abiraterone?
Monday, 18th December 2017
From Roger Wotton, Chairman of Tackle
As you may know, NICE is undertaking an appraisal for Abiraterone for treating newly diagnosed high risk prostate cancer patients who have metastatic disease. The committee will consider the treatment on 10 May 2018 and the deadline for nominating experts is 2 January.
Two patient expert witnesses are being sought to participate in this appraisal. We have been asked by Prostate Cancer UK if we can help in this matter. The purpose of this note is to ask if you have a member of your group you would wish to put forward as a patient . It would also be helpful to know if they have been involved in either the LATITUDE or STAMPEDE trials.
The criteria for being a patient expert witness in this Abiraterone appraisal are:
- To be taking or have taken Abiraterone in combination with hormone therapy
- To have a Gleason score of 8 or more
- To have three or more metastases in the bones
- To have any metastases in the liver or any other organs other than the lymph nodes or bones
All of these criteria have to be met for the patient expert witness. Not to have been through chemotherapy would also be preferable but not a necessary criteria.
If you wish to put a name forward please email me at email@example.com by December 22nd.